Vistin Pharma ASA
OSE:VISTN
Vistin Pharma ASA
Revenue
Vistin Pharma ASA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
V
|
Vistin Pharma ASA
OSE:VISTN
|
Revenue
kr429.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
![]() |
Photocure ASA
OSE:PHO
|
Revenue
kr525.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
N
|
Navamedic ASA
OSE:NAVA
|
Revenue
kr531.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
23%
|
CAGR 10-Years
9%
|
|
S
|
SoftOx Solutions AS
OSE:SOFTX
|
Revenue
kr13.3m
|
CAGR 3-Years
29%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
Vistin Pharma ASA
Glance View
Vistin Pharma ASA engages in the manufacture and sale of metformin products. The company is headquartered in Oslo, Oslo. The company went IPO on 2015-06-10. The company was created as a result of spin-off of Weifa AS. The company specializes in manufacture of Active Pharmaceutical Ingredients (API) and Solid Dosage Forms. Its products portfolio is comprised of Metformin, Pholcodine and Codeine Phosphate, among others. The firm's products are sold domestically and abroad, including markets in Asia, America, Africa and Europe.
See Also
What is Vistin Pharma ASA's Revenue?
Revenue
429.5m
NOK
Based on the financial report for Dec 31, 2024, Vistin Pharma ASA's Revenue amounts to 429.5m NOK.
What is Vistin Pharma ASA's Revenue growth rate?
Revenue CAGR 5Y
14%
Over the last year, the Revenue growth was -1%. The average annual Revenue growth rates for Vistin Pharma ASA have been 16% over the past three years , 14% over the past five years .